Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightThese results support the use of brexpiprazole as part of personalized treatment plans.
📌 3 Maddede Bu Makale
Özet
This case series focuses on the use of brexpiprazole in the management of agitation associated with dementia. Dementia is characterized by cognitive and functional impairments, as well as behavioral symptoms such as agitation, anxiety, and depression. A multidisciplinary approach is required for treatment, with pharmacological interventions carefully evaluated. The effects of brexpiprazole were examined in patients with three different types of dementia (vascular, frontotemporal, and Alzheimer’s). Treatment was administered in doses ranging from 0.5 to 2 mg/day, and a reduction in agitation symptoms was observed in all cases. In Case 1 (vascular dementia), agitation markedly decreased, while in Case 2 (frontotemporal dementia), the patient’s social and daily functionality improved. In Case 3 (Alzheimer’s dementia), sleep disturbances were alleviated, although dizziness and falls necessitated dose reduction. The findings suggest that brexpiprazole may be an effective option for treating agitation associated with dementia. The drug’s multi-receptor effects contribute to symptom improvement, while its side effects may vary among individuals. These results support the use of brexpiprazole as part of personalized treatment plans.
Abstract
This case series focuses on the use of brexpiprazole in the management of agitation associated with dementia. Dementia is characterized by cognitive and functional impairments, as well as behavioral symptoms such as agitation, anxiety, and depression. A multidisciplinary approach is required for treatment, with pharmacological interventions carefully evaluated. The effects of brexpiprazole were examined in patients with three different types of dementia (vascular, frontotemporal, and Alzheimer’s). Treatment was administered in doses ranging from 0.5 to 2 mg/day, and a reduction in agitation symptoms was observed in all cases. In Case 1 (vascular dementia), agitation markedly decreased, while in Case 2 (frontotemporal dementia), the patient’s social and daily functionality improved. In Case 3 (Alzheimer’s dementia), sleep disturbances were alleviated, although dizziness and falls necessitated dose reduction. The findings suggest that brexpiprazole may be an effective option for treating agitation associated with dementia. The drug’s multi-receptor effects contribute to symptom improvement, while its side effects may vary among individuals. These results support the use of brexpiprazole as part of personalized treatment plans.